/ EN

Mobile

Shandong LINUO Pharmaceutical Co., Ltd.
ADD:Ji'nan No. ten East Road 30766 Connaught Technology Park
MAP>>

Business advisory telephone:0531-88729642

E-MAIL:lnyybgs@lnphar.com

WeChat

Profile

IMG

 
   In August 2002 Shandong Linuo Pharmaceutical Co., Ltd   was founded by Shandong Linuo Group and located in Jinan high and new technology industry area, focused on CNS , chronic disease, oncological and cardiovascular drug .  It is a high-technology enterprise which integrating R&D of  Chemical-pharmaceutical  preparations , production and sales . 
 
   There are 39 products approvals , including 1 Second Sorts of New Drugs , 3 First Generic Drugs, 28 National Additional Basic Drugs and 30 National  Medical  Insurance Products .
The company is located in Linuo Science & Technology Park. Registered capital is about 88.8 million and total fixed assets is about 130 million . It covers  an area of 37000 square meters . Workshops are built up for producing tablets, capsules, pastes and aerosol with affiliated facilities and  all  production lines are certificated by Current  GMP. Annual production  capacity is about 800 million tablets/capsules , 30 million pieces of pastes and 30 million pieces of aerosols . 
 
   We won ‘ Faster Growth Enterprise in China Pharmaceutical Industry Award 2017 ’ which was issued by Ministry of industry  and information technology  of People's Republic of  China.  It shows that with the improvement of product line layout, market development,marketing, quality assurance and brand building, Linuo Pharma has entered a stage of rapid development .
 
    The core product Fluoxetine HCl Dispersible tablet became Shandong Innovation Project which is approved by Shandong Economic and Information Technology Committee. Pediatric Promethazine HCl tablets has successfully been selected by National Insurance Directory 2017  , code 1172 . It became the only National exclusive medical insurance, exclusive generic products which under this code .
 
9 of the core products will complete the Conformity Evaluation during 2019 to 2020. 2 of these products will be the exclusive products which complete the Conformity Evaluation. 3 products are expected to be the domestic first three and there will  be  preferential treatment for biding.
 
   Based on the principle of  “Healthy China , Hand on Heart ” Shandong Linuo Pharmaceutical Co., Ltd  occupied the China medicine market and expanded  overseas market actively. We always adhering to the“Serve the country through industry to benefit people, Serve the society by achieving excellence” business philosophy,  by being grateful for  taking social responsibility .
 
 
 
 
IMG